Key result
Dahuang zhechong pill reverses doxorubicin resistance and inhibits resistant hepatocellular carcinoma xenograft growth in mice.
Why the study?
Dahuang zhechong pill (DHZCP) is commonly used clinically for liver cancer, but its ability to reverse doxorubicin resistance in hepatocellular carcinoma was not investigated.
Does Dahuang zhechong pill reverse doxorubicin resistance in a doxorubicin-resistant SMMC-7721 xenograft mouse model?
Does Dahuang zhechong pill reverse doxorubicin resistance in a doxorubicin-resistant SMMC-7721 xenograft mouse model?
In a preclinical model, Dahuang zhechong pill reversed doxorubicin resistance in hepatocellular carcinoma xenografts by promoting apoptosis and reducing energy metabolism.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for DHZCP in liver cancer models; leaves open translation to human therapy.
ETHNOPHARMACOLOGICAL RELEVANCE: Dahuang zhechong pill (DHZCP) is a famous traditional Chinese medicinal prescription from the "Synopsis of Prescriptions of the Golden Chamber (Jin Kui Yao Lue)",Lue)", an ancient Chinese medical classic. DHZCP is commonly used for clinical treatment of liver cancer by promoting blood circulation to dissolve blood stasis and by removing pathogenic vegetations.vegetations. DHZCP-based treatment has been derived from Traditional Chinese Medicine (TCM) and is officially recorded in the Chinese Pharmacopoeia. AIM OF THE STUDY: The aim of this study was to investigate the ability of DHZCP to reverse doxorubicin (DOX) resistance of SMMC-7721 cells in a xenograft mouse model, and to explore the underlying mechanisms. MATERIALS AND METHODS: Liquid chromatography-mass spectrometry was used to verify the composition of DHZCP. H&E staining was used to observe the pathological changes in hepatocellular carcinoma samples. Intracellular DOX accumulation was observed as intrinsic fluorescence by microscopy. Cell apoptosis was detected by the TUNEL assay. Human antibody arrays were used to analyze the expression of apoptotic- and angiogenic-related proteins. ATP levels were assessed and western blots were used to detect the protein expression of key enzymes of energy metabolism. RESULTS: DHZCP significantly reduced the tumor volume and weight of subcutaneous xenografts of drug-resistant hepatoma cells, and combining DHZCP with lower doses of DOX significantly increased the content of DOX in tumor tissue, increased the apoptosis of hepatoma cells, and reversed Dox resistance. With respect to 43 apoptosis-associated proteins, DHZCP regulated the expression of 5 of them. When combined with low-dose DOX, the expression of 40 apoptosis-related proteins was significantly altered. With respect to 23 angiogenesis-associated proteins, DHZCP upregulated the expression of endostatin and inhibited the expression of matrix metallopeptidase 9. When combined with low-dose DOX, DHZCP significantly downregulated protein expression of urokinase receptor, as well as vascular endothelial growth factor receptors 2 and 3. Especially, DHZCP significantly inhibited the expression of key enzymes of the tricarboxylic acid cycle and of oxidative phosphorylation, reducing the level of ATP in tumor tissue. CONCLUSIONS: DHZCP inhibited the growth of DOX-resistant hepatocellular carcinoma subcutaneous xenografts in nude mice and promoted increased apoptosis caused by DOX, thus reversing DOX resistance. This was associated with a decline in energy metabolism and regulated expression of pro-apoptotic proteins.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2018) studied Doxorubicin-resistant hepatocellular carcinoma (SMMC-7721 xenografts). Dahuang zhechong pill (DHZCP) with or without doxorubicin was evaluated on Tumor volume and weight, apoptosis, and DOX resistance. Dahuang zhechong pill inhibited the growth of DOX-resistant hepatocellular carcinoma xenografts in mice and promoted increased apoptosis when combined with DOX, reversing DOX resistance.
Synapse has enriched 10 related papers. Consider them for comparative context: